BRIEF-European Medicines Agency validates Gilead's marketing authorization application for investigational chronic hepatitis C therapy
January 20, 2017 at 06:16 AM EST
* European Medicines Agency validates Gilead's marketing authorization application for investigational chronic hepatitis c therapy sofosbuvir/velpatasvir/voxilaprevir (sof/vel/vox)